GlassScriptPhysician profile
Kris Magpantay
NPI 1598240269
$12,251.91
in general payments reported to CMS, 2019-2025
27 companies · $4,927 in 2025
The $4,927 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $874 · 2022: $635 · 2023: $2,109 · 2024: $3,707 · 2025: $4,927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,502.62 |
| Education | $239.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,830.67 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,588.17 | 2021-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $1,361.83 | 2023-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $1,297.26 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $783.63 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $769.74 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Abbvie INC. | $706.32 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $691.68 | 2021-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $526.71 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $499.85 | 2023-2025 | Spravato, Invega Sustenna |
| Indivior INC. | $471.64 | 2023-2024 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $384.39 | 2025 | Cobenfy |
| Bausch Health US, LLC | $299.90 | 2023-2025 | Aplenzin, Wellbutrin |
| Takeda Pharmaceuticals U.S.A., INC. | $265.39 | 2022-2025 | Trintellix |
| Axsome Therapeutics, INC. | $190.29 | 2025 | Auvelity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $132.78 | 2022-2024 | Nuplazid |
| Noven Therapeutics, LLC | $108.17 | 2023-2025 | Secuado, Xelstrym |
| Avanir Pharmaceuticals, INC. | $90.87 | 2021-2022 | |
| Corium, LLC | $67.69 | 2025 | Azstarys |
| Genentech USA, INC. | $38.54 | 2021 | |
| Tris Pharma INC | $33.46 | 2024-2025 | Dyanavel Xr |
| Jazz Pharmaceuticals INC. | $23.49 | 2022 | |
| Idorsia Pharmaceuticals US INC | $22.83 | 2024 | Quviviq |
| Novo Nordisk INC | $20.00 | 2021 | |
| Collegium Pharmaceutical, INC. | $15.92 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $15.57 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $15.12 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kris Magpantay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.